Compare Citius Pharmaceuticals Inc (CTXR) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Harmony Gold Mining Co. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B). The key difference: Harmony Gold Mining Co. is far larger — about 735.7× Citius Pharmaceuticals Inc's market cap, and Harmony Gold Mining Co. pays a 4.63% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Harmony Gold Mining Co. for 45 Days on average.
| CTXR | HMY | |
|---|---|---|
Market Cap | $13.62M | $10.02B |
Volume | 132,438 | 3,643,683 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $26.04 |
52-Week Low | $0.48 | $13.32 |
Typical Hold Time | 17 Days | 45 Days |
Enterprise Value | $3.79M | $10.07B |
Dividend Yield | — | 4.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Harmony Gold Mining (HMY) trades at $16.84, up 2.12% today, showing strong profitability with 29.57% net margins and robust cash flow generation. The stock appears fundamentally undervalued with a P/E of 6.02 and EV/EBITDA of 3.54, though technical indicators signal bearish momentum with the price near key support levels. Recent earnings showed mixed results with two beats and two misses, while the company continues its strategic transition toward copper production diversification.
HMY presents a compelling value opportunity given its attractive valuation multiples and strong operational performance, but faces near-term technical headwinds and execution risks in its copper expansion strategy. The bearish technical setup and cautious analyst consensus (70% hold rating) suggest patience may be warranted despite the company's solid fundamentals and record fiscal 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
